Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Growth (Status and Outlook) 2022-2028
- LP 4883400
- 101 Pages
- March 2022
- Pharmaceuticals
The United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, reaching US$ million by the year 2028. As for the Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Progressive Familial Intrahepatic Cholestasis Type 2 Treatment players cover Teva, AbbVie, Glenmark Pharmaceuticals, and Par Pharmaceuticals, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Ursodeoxycholic Acid
Cholestyramine
Rifampicin
Late Stage Pipeline Drugs
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Teva
AbbVie
Glenmark Pharmaceuticals
Par Pharmaceuticals
Mylan
Sanofi
Novartis
Akorn
Albireo Pharma
Mirum Pharmaceuticals
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2017-2028
2.1.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Segment by Type
2.2.1 Ursodeoxycholic Acid
2.2.2 Cholestyramine
2.2.3 Rifampicin
2.2.4 Late Stage Pipeline Drugs
2.2.5 Others
2.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
2.3.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Type (2017-2022)
2.4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
2.5.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application (2017-2022)
3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Player
3.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Players
3.1.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue by Players (2020-2022)
3.1.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Players (2020-2022)
3.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment by Regions
4.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Regions (2017-2022)
4.2 Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth (2017-2022)
4.3 APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth (2017-2022)
4.4 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth (2017-2022)
4.5 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth (2017-2022)
5 Americas
5.1 Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2017-2022)
5.2 Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2017-2022)
5.3 Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2017-2022)
6.2 APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2017-2022)
6.3 APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment by Country (2017-2022)
7.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2017-2022)
7.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment by Region (2017-2022)
8.2 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2017-2022)
8.3 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast by Regions (2023-2028)
10.1.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast by Regions (2023-2028)
10.1.2 Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast
10.1.3 APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast
10.1.4 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast
10.1.5 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast
10.2 Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast by Country (2023-2028)
10.2.1 United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.2.2 Canada Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.2.3 Mexico Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.2.4 Brazil Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.3 APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast by Region (2023-2028)
10.3.1 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.3.2 Japan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.3.3 Korea Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.3.4 Southeast Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.3.5 India Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.3.6 Australia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.4 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast by Country (2023-2028)
10.4.1 Germany Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.4.2 France Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.4.3 UK Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.4.4 Italy Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.4.5 Russia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.5 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast by Region (2023-2028)
10.5.1 Egypt Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.5.2 South Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.5.3 Israel Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.5.4 Turkey Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.5.5 GCC Countries Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Forecast
10.6 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast by Type (2023-2028)
10.7 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Teva
11.1.1 Teva Company Information
11.1.2 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.1.3 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Teva Main Business Overview
11.1.5 Teva Latest Developments
11.2 AbbVie
11.2.1 AbbVie Company Information
11.2.2 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.2.3 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 AbbVie Main Business Overview
11.2.5 AbbVie Latest Developments
11.3 Glenmark Pharmaceuticals
11.3.1 Glenmark Pharmaceuticals Company Information
11.3.2 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.3.3 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Glenmark Pharmaceuticals Main Business Overview
11.3.5 Glenmark Pharmaceuticals Latest Developments
11.4 Par Pharmaceuticals
11.4.1 Par Pharmaceuticals Company Information
11.4.2 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.4.3 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Par Pharmaceuticals Main Business Overview
11.4.5 Par Pharmaceuticals Latest Developments
11.5 Mylan
11.5.1 Mylan Company Information
11.5.2 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.5.3 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Mylan Main Business Overview
11.5.5 Mylan Latest Developments
11.6 Sanofi
11.6.1 Sanofi Company Information
11.6.2 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.6.3 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 Sanofi Main Business Overview
11.6.5 Sanofi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.7.3 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 Akorn
11.8.1 Akorn Company Information
11.8.2 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.8.3 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.8.4 Akorn Main Business Overview
11.8.5 Akorn Latest Developments
11.9 Albireo Pharma
11.9.1 Albireo Pharma Company Information
11.9.2 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.9.3 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.9.4 Albireo Pharma Main Business Overview
11.9.5 Albireo Pharma Latest Developments
11.10 Mirum Pharmaceuticals
11.10.1 Mirum Pharmaceuticals Company Information
11.10.2 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
11.10.3 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue, Gross Margin and Market Share (2020-2022)
11.10.4 Mirum Pharmaceuticals Main Business Overview
11.10.5 Mirum Pharmaceuticals Latest Developments
12 Research Findings and Conclusion
Table 1. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Ursodeoxycholic Acid
Table 3. Major Players of Cholestyramine
Table 4. Major Players of Rifampicin
Table 5. Major Players of Late Stage Pipeline Drugs
Table 6. Major Players of Others
Table 7. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 9. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Type (2017-2022)
Table 10. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 11. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 12. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application (2017-2022)
Table 13. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue by Players (2020-2022) & ($ Millions)
Table 14. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Player (2020-2022)
Table 15. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Key Players Head office and Products Offered
Table 16. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Regions 2017-2022 & ($ Millions)
Table 20. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Regions (2017-2022)
Table 21. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2017-2022) & ($ Millions)
Table 22. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Country (2017-2022)
Table 23. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 24. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Type (2017-2022)
Table 25. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 26. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application (2017-2022)
Table 27. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2017-2022) & ($ Millions)
Table 28. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Region (2017-2022)
Table 29. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 30. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Type (2017-2022)
Table 31. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 32. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application (2017-2022)
Table 33. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2017-2022) & ($ Millions)
Table 34. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Country (2017-2022)
Table 35. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 36. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Type (2017-2022)
Table 37. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 38. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application (2017-2022)
Table 39. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2017-2022) & ($ Millions)
Table 40. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Region (2017-2022)
Table 41. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 42. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Type (2017-2022)
Table 43. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 44. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application (2017-2022)
Table 45. Key Market Drivers & Growth Opportunities of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment
Table 46. Key Market Challenges & Risks of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment
Table 47. Key Industry Trends of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment
Table 48. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 49. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share Forecast by Regions (2023-2028)
Table 50. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 51. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share Forecast by Type (2023-2028)
Table 52. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 53. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share Forecast by Application (2023-2028)
Table 54. Teva Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 55. Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 56. Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 57. Teva Main Business
Table 58. Teva Latest Developments
Table 59. AbbVie Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 60. AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 61. AbbVie Main Business
Table 62. AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 63. AbbVie Latest Developments
Table 64. Glenmark Pharmaceuticals Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 65. Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 66. Glenmark Pharmaceuticals Main Business
Table 67. Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 68. Glenmark Pharmaceuticals Latest Developments
Table 69. Par Pharmaceuticals Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 70. Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 71. Par Pharmaceuticals Main Business
Table 72. Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 73. Par Pharmaceuticals Latest Developments
Table 74. Mylan Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 75. Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 76. Mylan Main Business
Table 77. Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 78. Mylan Latest Developments
Table 79. Sanofi Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 80. Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 81. Sanofi Main Business
Table 82. Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 83. Sanofi Latest Developments
Table 84. Novartis Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 85. Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 86. Novartis Main Business
Table 87. Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 88. Novartis Latest Developments
Table 89. Akorn Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 90. Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 91. Akorn Main Business
Table 92. Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 93. Akorn Latest Developments
Table 94. Albireo Pharma Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 95. Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 96. Albireo Pharma Main Business
Table 97. Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 98. Albireo Pharma Latest Developments
Table 99. Mirum Pharmaceuticals Details, Company Type, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Area Served and Its Competitors
Table 100. Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
Table 101. Mirum Pharmaceuticals Main Business
Table 102. Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 103. Mirum Pharmaceuticals Latest Developments
List of Figures
Figure 1. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Type in 2021
Figure 7. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment in Hospital Pharmacies
Figure 8. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Hospital Pharmacies (2017-2022) & ($ Millions)
Figure 9. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment in Retail Pharmacies
Figure 10. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Retail Pharmacies (2017-2022) & ($ Millions)
Figure 11. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment in Online Pharmacies
Figure 12. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Online Pharmacies (2017-2022) & ($ Millions)
Figure 13. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application in 2021
Figure 14. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Player in 2021
Figure 15. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Regions (2017-2022)
Figure 16. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2017-2022 ($ Millions)
Figure 17. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2017-2022 ($ Millions)
Figure 18. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2017-2022 ($ Millions)
Figure 19. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2017-2022 ($ Millions)
Figure 20. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Value Market Share by Country in 2021
Figure 21. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Consumption Market Share by Type in 2021
Figure 22. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application in 2021
Figure 23. United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 24. Canada Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 25. Mexico Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 26. Brazil Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 27. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Region in 2021
Figure 28. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application in 2021
Figure 29. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 30. Japan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 31. Korea Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 32. Southeast Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 33. India Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 34. Australia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 35. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Country in 2021
Figure 36. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Type in 2021
Figure 37. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application in 2021
Figure 38. Germany Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 39. France Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 40. UK Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 41. Italy Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 42. Russia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 43. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Region in 2021
Figure 44. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Type in 2021
Figure 45. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Market Share by Application in 2021
Figure 46. Egypt Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 47. South Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 48. Israel Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 49. Turkey Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 50. GCC Country Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 51. Americas Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 52. APAC Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 53. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 54. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 55. United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 56. Canada Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 57. Mexico Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 58. Brazil Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 59. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 60. Japan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 61. Korea Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 62. Southeast Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 63. India Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 64. Australia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 65. Germany Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 66. France Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 67. UK Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 68. Italy Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 69. Russia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 70. Spain Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 71. Egypt Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 72. South Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 73. Israel Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 74. Turkey Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Figure 75. GCC Countries Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size 2023-2028 ($ Millions)
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
